|
April 2009 (Volume 16, Issue 4)
|
   |
Article: 598
Pfizer’s Enhanced Clinical Trial Design Saves $100 Million Annually
Late-phase failure is an industry wide problem. Pfizer’s initiative, Enhanced Clinical Trial Design (ECTD), uses established statistical modeling approaches in an innovative manner to better size clinical trials and to stop inefficient drugs earlier.
Article: 599
Clinical Trial Industry Embraces Online Social Networking
Originally created as a way for teens to keep in touch, social networking platforms, such as Facebook, MySpace and LinkedIn, have exploded into the adult arena with an increasing number of professionals using them to reconnect, network and market themselves and their businesses.
Article: 600
EMEA’s New Pharmacovigilance Head Makes Immediate Impact
Dr. Peter Arlett was appointed head of the European Medicines Agency (EMEA) sector for pharmacovigilance and risk management just a few months ago, but he has wasted no time readying the agency to implement a string of big initiatives during a time of great change for the EMEA as a whole.
Article: 601
Eye On: Epilepsy/Seizure Disorders
Epilepsy is a neurological disease characterized by seizures, or fits, causing loss of consciousness and/or generalized or focal neurological symptoms and signs, such as convulsions, abnormal behaviors and emotions, and/or unusual sensations or movements.
Price: $59.00
|